NICE Recommends Gilead’s Bulevertide for Hepatitis Delta Virus
The UK’s National Institute for Health and Care Excellence (NICE) has announced its approval of Gilead Sciences’ bulevirtide for the treatment of hepatitis delta virus (HDV) in adults with compensated liver disease. This recommendation comes after the US Food and Drug Administration (FDA) shot down Gilead’s application for issues with manufacturing and delivery.
